Which Biopharmas Are Best Positioned For Five-Year Growth?
Morningstar expects 229% revenue growth during the 2015-2020 period for BioMarin, far stronger than larger competitors. Virology powerhouse Gilead is the only one of the 20 largest biopharmas expected to face a decline in revenue over the period.
You may also be interested in...
The Phase III failure of the Alzheimer’s treatment was largely expected, but is nonetheless a disappointment for the disease and for the anti-amyloid field, casting a shadow over other therapies in development, including Lilly’s own pipeline.
AstraZeneca's CEO Pascal Soriot says change is inevitable for pharma after Donald Trump's election win and the UK's decision to leave the EU and that dialogue with governments will be necessary to ensure key benefits of globalization enjoyed by the sector are retained.
During third-quarter earnings report, Brandicourt said he remains confident about Sanofi's prospects in oncology despite losing the takeover fight for Medivation, although he didn't rule out another mid-sized bolt-on attempt if the opportunity arose.